Verastem (VSTM) Reports Q4 Loss Per Share of 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
March 12, 2019 4:08 PM EDTU.S. Commercial Launch of COPIKTRA Underway
$1.7 Million in 2018 Net Product Revenues from COPIKTRA
Cash, Cash Equivalents and Short-Term Investments of $249.7 million as December 31, 2018
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology, (or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today reported financial results for the three and twelve months ended December 31, 2018, including revenue from its first commercial product, COPIKTRA (duvelisib), which was approved by the U.S. Food and Drug... More
